Sysmex (OTCMKTS:SSMXY) Reaches New 12-Month Low - Here's What Happened

Key Points

• Sysmex Corporation ADR reached a new 52-week low at $12.00 during trading, ending at $12.37 with a trading volume of 68,253 shares.
• Despite the stock's recent decline, Zacks Research upgraded Sysmex from a "strong sell" to a "hold" rating, contributing to a consensus rating of "Hold" among analysts.
• In its latest quarterly earnings, Sysmex reported a loss of $0.07 per share compared to estimates and fell short of revenue expectations, generating $717.09 million against a forecast of $807.27 million.

Sysmex Corporation ADR (OTCMKTS:SSMXY - Get Free Report) hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $12.00 and last traded at $12.37, with a volume of 68253 shares trading hands. The stock had previously closed at $12.60.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded shares of Sysmex from a "strong sell" rating to a "hold" rating in a research report on Thursday, August 14th. One analyst has rated the stock with a Hold rating, According to data from MarketBeat, the company currently has a consensus rating of "Hold".

Sysmex Trading Down 1.8%

The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.49 and a current ratio of 3.37. The firm's fifty day simple moving average is $14.13 and its 200-day simple moving average is $16.52. The stock has a market cap of $7.79 billion, a P/E ratio of 24.74 and a beta of 1.10.

Sysmex (OTCMKTS:SSMXY - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.07). Sysmex had a return on equity of 10.20% and a net margin of 9.35%.The firm had revenue of $717.09 million for the quarter, compared to analyst estimates of $807.27 million. Equities research analysts expect that Sysmex Corporation ADR will post 0.57 EPS for the current fiscal year.

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.